Target intelligence / Profile preview

BH3-interacting domain death agonist (BID)

Target
BID
Molecular classification
Bcl-2 family, BH3-only protein, Pro-apoptotic protein, Other
01

Overview

BH3-interacting domain death agonist (BID) is a pro-apoptotic member of the BCL-2 protein family that serves as a critical molecular bridge between the extrinsic (death receptor-mediated) and intrinsic (mitochondrial) apoptotic pathways. In its inactive state, BID resides in the cytosol. Upon receiving apoptotic stimuli, such as death receptor activation, BID is cleaved by caspase-8 or other proteases to form its active, truncated counterpart, tBID. Active tBID translocates to the outer mitochondrial membrane, where it directly activates the pro-apoptotic effectors BAX and BAK, leading to mitochondrial outer membrane permeabilization (MOMP), the release of cytochrome c and SMAC/DIABLO, and subsequent caspase activation.

Dysregulation of BID is heavily implicated in various pathologies, including cancer, where its downregulation or inactivation contributes to apoptotic resistance and chemotherapy evasion. Conversely, hyperactivation of BID-mediated cell death is associated with neurodegenerative diseases, stroke, and ischemic injuries. Consequently, BID is a highly attractive therapeutic target. Small-molecule inhibitors of BID (such as BI-6C9 and BI-11A7) are being investigated to prevent pathological cell death in neurodegeneration and ischemia. On the other hand, BH3 mimetics (such as venetoclax and navitoclax) mimic the BH3 domain of BID and other BH3-only proteins to neutralize anti-apoptotic BCL-2 family members, thereby restoring the apoptotic cascade in cancer cells.

Other names
p22 BIDFP497Cytochrome c Releasing Factor 1CCRF 1Truncated BidtBidp15 BIDp13 BIDp11 BID
02

Mechanism of action

Direct small-molecule inhibitors (such as BI-6C9 and BI-11A7) bind to BID and prevent its cleavage into active truncated BID (tBID), thereby blocking mitochondrial outer membrane permeabilization (MOMP) and protecting cells from apoptosis. Conversely, BH3 mimetics (such as venetoclax, navitoclax, and obatoclax) mimic the BH3 domain of BID and other BH3-only proteins to competitively bind anti-apoptotic BCL-2 family proteins, displacing endogenous BID/tBID to promote apoptosis in cancer cells.

03

Biological functions

ApoptosisCell deathMitochondrial outer membrane permeabilizationSignal transductionOther
04

Disease associations

CancerNeurodegenerative diseaseInflammationCardiovascular diseaseOther
05

Safety considerations

Risk of tumorigenesis or cancer development due to impaired clearance of damaged cells when BID is inhibitedResistance to death receptor-mediated apoptosis (such as Fas/CD95 and TRAIL) upon BID inhibitionOn-target toxicities in healthy tissues (such as thrombocytopenia, neutropenia, and lymphopenia) when using BH3 mimeticsRisk of tumor lysis syndrome (TLS) due to rapid tumor cell deathDevelopment of drug resistance through compensatory upregulation of other anti-apoptotic proteins like MCL-1 or BCL-XL
06

Interacting drugs

BI-6C9

6 more in the full profile.

07

Biomarkers

BID expression levelstBID (truncated BID) levelsBAX/BCL-2 ratioCytochrome c releaseSMAC/DIABLO releaseApoptosis-inducing factor (AIF) nuclear translocation

Beyond the preview

Go deeper on BH3-interacting domain death agonist (BID).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on BH3-interacting domain death agonist (BID).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call